This finding of a lower abundance of CD8+ T cells expressing canonical immune inhibitory–related markers in AML has important clinical significance, partially explaining the limited efficacy of immune checkpoint inhibitors observed in AML patients, in contrast to remarkable responses seen in some solid tumors. The gene discussed is CD8A; the disease is acute myeloid leukemia.